Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neuronetics Inc STIM

Healthcare Medical Devices
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength... see more

Recent & Breaking News (NDAQ:STIM)

Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer

GlobeNewswire May 1, 2023

Neuronetics Announces Expanded TMS Access through United HealthCare

GlobeNewswire April 28, 2023

Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call

GlobeNewswire April 25, 2023

Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy

GlobeNewswire April 13, 2023

NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities

GlobeNewswire April 6, 2023

Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note

GlobeNewswire April 4, 2023

NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA

GlobeNewswire March 16, 2023

Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results

GlobeNewswire March 7, 2023

Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives

GlobeNewswire March 2, 2023

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 27, 2023

Neuronetics Expands NeuroStar® Advanced Therapy's Proprietary TrakStar® Platform

GlobeNewswire February 23, 2023

Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call

GlobeNewswire February 22, 2023

Neuronetics Sponsors the 5th International Brain Stimulation Conference

GlobeNewswire February 21, 2023

Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer

GlobeNewswire February 16, 2023

Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners

GlobeNewswire February 10, 2023

Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership

GlobeNewswire January 19, 2023

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 18, 2023

Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health

GlobeNewswire January 17, 2023

Neuronetics Settles Litigation Against BrainsWay

GlobeNewswire January 10, 2023

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results

GlobeNewswire January 9, 2023